Projects
Antibodies! The adaptive immune response can provide perfectly fitting antibodies for anything you can imagine, given enough time, repetitive exposure and some magic. Surprisingly, there are still many black boxes in the process of antibody generation.
Core aim:
We aim to understand the regulation and mechanism of antigen-driven selection during B cell affinity maturation.
Simple is rarely easy:
High-affinity antibodies are a hallmark of effective vaccination, can provide long-lasting protection and are affinity matured in the germinal center (GC). In a bird's-eye view humoral adaptive immunity is well understood, but the little unknown details are crucial to understand the difference between failure and success. Little things make big things happen.
Sweet Germinal Centers
Germinal Centers (GC) are the central hubs where B cells fine-tune the affinity of their B cell receptor (BCR, membrane bound antibody). This affinity maturation is crucial for effective antibody responses as well as memory formation. It has long been known that activated GC stain positive with peanut agglutinin (PNA), while inactive follicles do not. Additionally, Solanum tuberosum agglutinin (STA) stains cellular subsets in the activated GC as well. Agglutinins bind specific sugar groups, such as sialic acids and other glycans. These sugar groups specifically change during active GC formation and glycans are known to signal in immune responses. This project focuses on the effect of sugar groups on adaptive immunity. The rationale for this project stems from our description of the follicular dendritic cell (FDC) transcriptome by single cell RNA sequencing. FDCs are stromal cells in the follicle with the capacity to regulate B and T cells. Our data revealed expression of several proteins involved in glycosylation. The first results of this line are out: we profiled N-glycans across human B-cell subsets and found that germinal center-associated glycan remodeling tracks with reduced recombinant CD22 binding, suggesting that the sugars on a B cell help set the thresholds it responds to. CD22 is one of the Siglecs, the family of sialic-acid-binding receptors that read these sugars and translate them into inhibitory signals. We follow a second member of that family, Siglec-6, into human memory B cells as part of the LLIMIT network.
Targeting follicular dendritic cells as therapy:
Antigens are retained and presented to B cells by FDCs, but for therapeutic purposes it can be useful to displace this antigen or modify its fate. An important question is if self-antigen is retained and if it contributes to undesired immune responses. In this project we investigate the role of FDCs in auto-antibody production by developing sophisticated tools to intervene in antigen fate. Retention of antigen by FDCs is mediated mainly by Complement and its receptors. However, there are more players that can determine the fate of the antigen. Fc-receptors can bind immune complexes, and TLRs can be activated, which all can influence the fate of the immune complex. Interestingly, retention of proteins in endosomal compartments is partly regulated by sugar groups. Glycosylation could very well influence the shuttling of immune complexes within FDCs. Decoy complement receptors or antibodies targeting the complement-binding site can be used to dissociate antigen from the FDC, but a more elegant solution might be to modify glycosylation. Antigen handling is not the only lever. We reported in 2021 that human FDCs express PD-L1 and PD-L2, and our 2026 paper in Immunity shows what that PD-L1 does: it restrains a Sostdc1-expressing subset of T follicular helper cells, which limits T follicular regulatory cell differentiation and keeps the germinal center productive. In autoimmune mouse models the same activity helps autoreactive germinal centers expand. That makes stromal PD-L1 a second handle on germinal center output, alongside antigen itself.
Germinal centers outside the body
Most of what we know about germinal centers comes from mice, and mice are not small people. To study human B-cell selection we need human tissue that still behaves like tissue, so we culture living slices of human tonsil that keep their follicular architecture intact. Within such a slice, B cells, T cells and the stromal network stay in the positions they occupy in vivo, which means a germinal center can form and be watched rather than reconstructed from dissociated cells. Luc has these cultures running for about five days, long enough to follow a response from activation onwards, and we use them to test how vaccines and adjuvants act on human tissue directly. The work is funded by Stichting Proefdiervrij, whose aim is to replace animal experiments, and that is also the point for us: a model that is human from the start removes a translation step instead of adding one. This platform feeds the other projects on this page. It is where we can ask whether a glycan change or an FDC signal actually moves a human germinal center, rather than inferring it.
High-dimensional image analysis
To analyze complex tissues such as germinal centers, we use advanced microscopy techniques that generate large, multi-channel datasets. Manual analysis of these datasets is time-consuming and prone to bias. Therefore, we are developing computational pipelines that leverage machine learning and image analysis tools to segment and classify cell types, as well as quantify biologically relevant proteins and glycans within these tissues. This approach enables us to efficiently extract meaningful biological insights from high-dimensional imaging data. Use the slider to compare a raw microscopy image (left) with the corresponding segmented and classified image (right), generated by our analysis pipeline.


Who we work with
Consortia and partnerships
Several of our projects run inside larger collaborations. These bring in expertise, materials and people we could not host alone.
GSK strategic partnership
A strategic partnership on the innate side of FDC biology. We showed that FDCs sense their environment through pattern recognition receptors, which are the classical targets of adjuvants, so the question is whether FDC-directed stimulation can be used to improve the quality of a vaccine response rather than only its size. Christian Martín Gil runs this project as a postdoc in the lab.
LLIMIT: lectin ligands for modulation of immunity
A Horizon Europe doctoral network that trains fourteen PhD candidates across seven European universities and six companies, all circling one idea: the sugar-binding receptors of the immune system, the galectins, C-type lectins and Siglecs, are plausible drug targets that almost nobody has seriously pursued. Candidates move between partners during their project, so chemistry, structural biology and immunology end up in the same pair of hands. Utrecht hosts two of the fourteen, one of them here. Our candidate asks what Siglec-6 does on human memory B cells. Siglec-6 sits almost exclusively on memory B cells and plasmablasts, where binding sialylated glycans appears to dampen B-cell receptor signalling and hold autoreactivity in check, but that role as a tolerance checkpoint has never been tested directly in human tissue. Using sialyl-Tn as a ligand, we will measure what engaging Siglec-6 does to B-cell activation, survival and tolerance in our tonsil slice cultures, and whether it reaches into CR2-dependent signalling. No animal models involved.
PHARMIGA: an infrastructure for IgA therapeutics
Nearly every therapeutic antibody on the market is an IgG. IgG works well in blood and poorly at mucosal surfaces, which is where a great deal of the trouble starts, and it is a weak recruiter of neutrophils. IgA is good at both, but it is harder to produce, awkward to characterise because of its glycosylation, and short-lived, so it has stayed a promising idea rather than a class of medicines. PHARMIGA, funded through ZonMw's PharmaNL programme, builds the shared infrastructure to change that, and opens it to outside academic and industrial users: mass spectrometry for IgA's glycans and epitopes, production of its monomeric, dimeric and secretory forms, formulation for delivery to lung and nose, and human models to test the result in. We work on that last part, following where IgA immune complexes travel in lymphoid tissue and testing IgA responses in human tonsil, alongside the airway and gut models of the other partners. The consortium is led from Utrecht with Sanquin, UMC Utrecht and PD-value.
Healthy Tattoo Consortium
We are an associate member of the HTC, led by UMCG Research, which studies what tattoo ink actually does in the body. Ink is deposited in the skin and drains to lymph nodes, which puts it in our territory: we look at the B-cell and germinal center side of the response. More about joining.
Where we have been
Earlier projects
Lines that shaped how we think, and that we still draw on. These are not the lab's current day-to-day focus.
Blocking Epstein-Barr Virus with complement
NWO ENW XS pilot · 2022–2024 The exact cause of MS remains unclear, especially why and how the nervous system is attacked. The adaptive immune system is the most likely culprit, as immunosuppressive treatments help manage the disease. One theory suggests molecular mimicry: neurons might express a protein similar to one from the Epstein-Barr virus (EBV), causing the immune system to mistakenly attack neurons. However, this doesn't fully explain the periodic "flares" seen in relapsing-remitting MS, as you'd expect constant attacks on those neurons. An alternative hypothesis is that EBV latently infects specific neuron subsets. Herpes viruses like EBV periodically reactivate, which could explain the flare-ups and why only certain neurons are affected. For this to happen, neurons would need the EBV entry receptor (CR2), which is also found on B cells and some immune cells with neuronal traits (i.e., follicular dendritic cells).
"In short: EBV may trigger MS by infecting neurons, with periodic reactivation causing flare-ups."Testing this needs a way to find functional CR2 on cells where transcript data is ambiguous, so the XS pilot went into building one: EBV gp350 NTD protein with fluorescent tags, used as a probe for the receptor rather than for the message. Ilhan Tomris, who had expressed a large part of the influenza and coronavirus surface protein catalogue, joined the lab for a few months to make it. The grant has ended; the hypothesis has not been settled.
Proofivy
Side project · started 2022 Proofivy came out of a question that has nothing to do with immunology: how do you show an idea was yours first, without having to publish it to prove it? The approach is to commit a hash of an experimental setup, assumption, hypothesis or draft to a public blockchain. The hash reveals nothing on its own, but once you publish the original, anyone can recompute it and see the date you committed it. That gives a timestamped, tamper-proof record without forcing you to disclose early.
"Proofivy's mission is to increase trust in science, journalism, and humanity. Blockchain technology provides us with new tools for verification and storing of data. Proofivy makes it easy for researchers (and anyone else), to prove the creation and possession of data before they are ready to share it, and to store and share untamperable data."The concept was developed with a friend who worked at Polygon, and supported by a small Polygon innovation fund grant. We built it and tested it on a real hypothesis of our own: the walkthrough of that commit, including how to verify it yourself on-chain, is written up in the LabNotes.
How projects are
Funded
Active funding
- GSK strategic partnership
- ZonMw VIDI grant
- Horizon Europe Doctoral Networks grant (Llimit consortium)
- ZonMw PharmaNL (PHARMIGA consortium)
Previous funding
- Ragon Innovation Award
- AMR postdoc fund
- NVVI work visit grant
- WBSO grant
- ZonMw VENI grant
- Polygon innovation fund
- NWO ENW XS grant
- Erasmus Scholarship to Melissa Ripamonti
- NWO Startersbeurs 2023
- Proefdiervrij Onderzoek grant



